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Abstract
Purpose Male breast cancer is associated with female
breast cancer in families but whether male breast cancer
clusters with other discordant cancers has not been studied.
As concordant male breast cancers are utterly rare, dis-
cordant associations of male breast cancer with other
cancers may reveal genetic and possible environmental risk
factors contributing to male breast cancer susceptibility.
Methods We calculated relative risks (RRs) for male
breast cancer in families with discordant cancers, and
conversely, for discordant cancers in families of male
breast cancer patients, based on 15.7 million individuals in
the Swedish Family-Cancer Database.
Results Among 1428 male breast cancer patients, 16.2%
had a female relative diagnosed with breast cancer. Ovar-
ian and female anal cancers showed the strongest associ-
ations with male breast cancer (p value\ 0.0005). The
other significant associations included colorectal, small
intestinal, and thyroid cancers, cancer of unknown primary
and non-Hodgkin lymphoma but these were each based on
a single positive association with male breast cancer. The
RRs for male breast cancer were increased in families in
which multiple patients were diagnosed with diverse can-
cers, reaching an RR of 2.58 when three or more family
members were affected.
Conclusions The results suggest that male breast cancer
shares susceptibility with a number of other cancers but
confirmation is needed in other datasets.
Keywords Familial cancer  Discordant cancer  Familial
risk  Genetic association
Introduction
The incidence of male breast cancer is only 1/200 of the
incidence of female breast cancer in Sweden and elsewhere
in the Western countries. The rareness of male breast
cancer has been a limitation for studying the role of family
history. Familial relative risks (RRs) have been approxi-
mately equal between male breast cancer with a female
family history as among females but data on male–male
risks are lacking [1–3]. Also are lacking data on possible
familial clustering of male breast cancer with other male or
female cancers. A study from 1991 reported an excess of
uterine cancers in relatives of male breast cancer patients
[1]. A very high risk (RR 93) of second male breast cancer
was noted by us and we also reported an increase in second
prostate cancers after male breast cancer [4, 5]. In an
international consortium on second cancers after male
breast cancer increases were observed for cancers at sev-
eral sites: the small intestine (RR 4.95), rectum (1.78),
pancreas (1.93), nonmelanoma skin (1.65), prostate (1.61),
and lymphohematopoietic system (1.63) [6]. It has been
shown that the frequency of deleterious BRCA1/2 muta-
tions is considerably higher in male breast cancer than in
female breast cancer, with BRCA2 being the most
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commonly mutated gene [7, 8]. The Swedish frequency
estimates for BRCA2 mutations were about 20% of male
breast cancer, as reviewed [8]. Several pathological fea-
tures were reported to distinguish breast cancer in male and
female carriers of BRCA1 and BRCA2 mutations, including
estrogen and progesterone receptor positivity [9]. BRCA2
mutations are known to increase risks for other cancers,
including ovarian, prostate and pancreatic cancers, and
uveal melanoma, and possible also esophageal and stomach
cancers [10]. Other predisposing genes for male breast
cancer may be PALB2,CHEK21100delC, and RAD50B
[9, 11]. Yet a review concluded that for most cases of male
breast cancer the causes remain unknown [12].
We investigated here familial associations of 1428 male
breast cancer with any cancer using the most recent update
of the Swedish Family-Cancer Database. The analyses for
other (discordant) cancers were based on a two-way
assessment of familial RRs for male breast cancer in
families with patients with another cancer X, and con-
versely in a reverse order, familial RRs for cancer X in
families with increasing numbers of patients with male
breast cancer. As the study included many comparisons, we
gave statistical significance of the results at three levels (5,
1, and 0.1%) and provided summary trend tests.
Methods
Swedish Family-Cancer Database (FCD) includes all
Swedish people born since 1932 (offspring generation)
with their biological parents (parental generation) [13]. The
latest version of this database contains 15.7 million indi-
viduals among which 1.8 million were cancer patients
recorded to the end of 2012. The three digital codes of
seventh revision of the International Classification of Dis-
eases (ICD-7) were used to identify 35 most common
primary cancers and cancer of unknown primary. However,
as many cancers were rare in male breast cancer families
we displayed data on discordant cancers based on a mini-
mum number of ten cases or a significant association
(p\ 0.05). The follow-up for cancer in offspring genera-
tion (8.5 million individuals) was started from the begin-
ning of 1958, the birth year, or the immigration year,
whichever came latest. The follow-up was terminated when
a person was diagnosed with cancer, emigrated, or died, or
at the end of 2012, whichever came first. The number of
first-degree relatives (including parents and/or siblings)
who were affected with cancer was considered as family
history.
Relative risks (RRs), calculated for the offspring gen-
eration, were used as a measure of assessing familial risks
by comparing incidence rates for persons with affected
relatives to incidence rates for those whose relatives had no
cancer. In the two-way comparison, firstly, RR for male
breast cancer was calculated when family history was
cancer X, and then in the reverse order RR for cancer X
was calculated when family history was male breast cancer.
For parents and offspring (large majority of familial cases)
these comparisons are independent but for siblings the
pairs of cases are the same. Significant results in two-way
analyses provide support for a true association but a lack-
ing two-way association is no strong evidence against an
association because age distributions and case numbers
may differ between two-way analyses.
Poisson regression model was employed to estimate
RRs and corresponding confidence intervals (CIs) for 5, 1,
and 0.1% significance levels. These can be combined to
calculate a joint significance for associations [14]. Trend
tests were performed by modeling the number of familial
cancers as a continuous covariate. Potential confounders,
including age group, sex, calendar period, residential area,
and socioeconomic status, were added to the model as
covariates. SAS version 9.4 was used to perform the sta-
tistical analysis.
The study was approved by the Ethical Committee of
Lund University.
Results
The total number of male breast cancers was 1428 and of
these 272 were diagnosed in the 0–80 year offspring gen-
eration for which RRs were calculated. No concordant
male–male breast cancers were found (expected number
0.11) but 16.2% of the offspring with male breast cancer
had at least one first-degree relative with female breast
cancer. The RR for male breast cancer was 1.76 when one
first-degree relative was diagnosed with female breast
cancer and in the reverse order RR for female breast cancer
was 1.90 when a first-degree relative was diagnosed with
male breast cancer (Table 1, also listing 95% CIs for all
RRs). Both of these RRs were significant at a 0.1% level
(joint significance 0.001 9 0.001\ 10-6). The reference
was families with no male breast cancers in first-degree
relatives with RR 1.00 (not shown). A total of 8 discordant
cancers are included in Table 1 (at least ten cases or a
significant positive association; no significant negative
associations were noted). Significant association for male
breast cancer were found with colorectal (1.47), anal
(4.64), and ovarian (2.20, 0.01% significance) cancers and
with cancer of unknown primary (1.94). The RR for male
breast cancer was 19.09 in a single family of two women
diagnosed with ovarian cancer (joint p value for male
breast cancer–ovarian cancer associations \0.0005). RRs
for all cancers (i.e., RR for male breast cancer when first-
degree relatives had any cancers) were highly significant
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and reached 2.58 (p\ 0.001) when at least three first-de-
gree relatives were diagnosed with any cancer, including
male breast cancer and female breast cancer. However, the
excess risk remained high when only discordant cancers
were included in first-degree relatives (no male or female
breast cancer included).
Table 2 shows results when only female first-degree
relatives were considered and only sites with significant
associations were shown. RRs were increased for female
small intestinal cancer (4.72) in families of male breast
cancer, and for male breast cancer in families of female
thyroid cancer (3.40) and non-Hodgkin lymphoma (2.46).
Anal cancer was increased in both of two-way analyses
(joint p\ 0.0005). RRs for all cancers were also increased.
Analysis of male breast cancer risks in families of male
cancer patients showed no significant associations. The
Table 1 Familial associations between male breast cancer and other cancers
Cancer site Patients with
no family
history
Cases with 1 affected
first-degree relative






N RR 95% CI N RR 95% CI N RR 95% CI
Colorectum
Risk of male breast cancer 239 33 1.47 1.02–2.12 – – – – – – 0.0478
Risk of colorectal cancer 35,334 26 1.32 0.90–1.93 – – – – – – 0.1801
Anus
Risk of male breast cancer 270 2 4.64 1.15–18.63 – – – – – – 0.0838
Risk of anal cancer 1086 2 3.22 0.80–12.88 – – – – – – 0.1664
Lung
Risk of male breast cancer 255 16 1.12 0.67–1.85 1 1.95 0.27–13.89 – – – 0.5371
Risk of lung cancer 24,364 13 0.94 0.55–1.62 – – – – – – 0.8233
Breast
Risk of male breast cancer 228 41 1.76 1.26–2.46 3 2.28 0.73–7.11 – – – 0.0010
Risk of breast cancer 76,250 82 1.90 1.53–2.36 – – – – – – <0.0001
Ovary
Risk of male breast cancer 265 6 1.23 0.55–2.77 1 19.09 2.68–136.06 – – – 0.2198
Risk of ovarian cancer 9958 12 2.20 1.25–3.88 – – – – – – 0.0157
Prostate
Risk of male breast cancer 233 36 1.32 0.93–1.88 2 1.27 0.32–5.12 1 6.38 0.89–45.53 0.0669
Risk of prostate cancer 61,825 39 1.11 0.81–1.52 – – – – – – 0.5117
Melanoma
Risk of male breast cancer 268 4 0.61 0.23–1.64 – – – – – – 0.2878
Risk of melanoma 28,481 15 1.01 0.61–1.67 0.9797
Non-Hodgkin lymphoma
Risk of male breast cancer 263 9 1.43 0.74–2.78 – – – – – – 0.3160
Risk of non-Hodgkin lymphoma 14,331 10 1.35 0.72–2.50 – – – – – – 0.3708
Cancer of unknown primary
Risk of male breast cancer 259 13 1.94 1.11–3.38 – – – – – – 0.0346
Risk of cancer of unknown primary 9165 6 1.18 0.53–2.63 – – – – – – 0.6919
All cancersa
Risk of male breast cancer 81 131 1.75 1.32–2.31 44 1.63 1.13–2.36 16 2.58 1.50–4.42 \0.0001
Risk of all cancers 428,558 290 1.24 1.10–1.39 – – – – – – 0.0004
All cancersb
Risk of male breast cancer 105 124 1.48 1.14–1.92 33 1.31 0.88–1.94 10 2.03 1.06–3.89 0.0074
Risk of all cancers 352,308 208 1.09 0.95–1.25 0.2040
Bold and bold italic values indicate that the 99% CI and 99.9% CI did not overlap with 1.00 respectively
a All cancers include breast cancer and all other cancers
b All cancers include all other cancers except breast cancer
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case numbers were so small that they provided null support
for the results in Table 2.
We identified multiple primary or in situ cancers when
male breast cancer patients were first-degree relatives
based on Table 1. The first of multiple cancers was always
male breast cancer (Table 3). Among breast cancer–male
breast cancer familial pairs 19 men had any multiple pri-
mary or in situ cancers, RR 2.20 (p\ 0.001). When the
multiple primary was prostate cancer the RR was 3.08
(p\ 0.001) and when it was squamous cell skin cancer the
RR was 4.58 (p\ 0.01). Among prostate–male breast
cancer familial pairs six men had both male breast cancer
and multiple prostate cancer, RR 2.65.
Discussion
The expected number of male–male breast cancer pairs was
0.11, indicating that this nation-wide study was under-
powered to find concordant cases of male breast cancer.
However, the present analyses provided novel results on
familial risk on male breast cancer. The RR between male
and female breast cancer equals the RR for concordant
female breast cancer which has been previously shown
[1–3]. Not only are familial risks matching between male
and female breast cancer but so are familial proportions:
16.2% of male breast cancer patients had a first-degree
relative with female breast cancer, while the percentage is
Table 2 Familial associations between male breast cancer and female cancers
Cancer site Patients with no family
history
Cases with 1 affected
first-degree relative






N RR 95% CI N RR 95% CI N RR 95% CI
Small intestine
Risk of male breast cancer 271 1 2.25 0.32–16.02 – – – – – – 0.4756
Risk of small intestinal
cancer
745 2 4.72 1.18–18.91 – – – – – – 0.0807
Colorectum
Risk of male breast cancer 254 18 1.59 0.97–2.57 – – – – – – 0.0748
Risk of colorectal cancer 16,119 14 1.52 0.90–2.57 – – – – – – 0.1409
Anus
Risk of male breast cancer 270 2 6.90 1.72–27.76 – – – – – – 0.0382
Risk of anal cancer 727 2 4.80 1.20–19.21 – – – – – – 0.0782
Lung
Risk of male breast cancer 263 9 1.68 0.87–3.28 – – – – – – 0.1549
Risk of lung cancer 12,061 9 1.28 0.67–2.41 – – – – – – 0.4740
Thyroid gland
Risk of male breast cancer 268 4 3.40 1.27–9.14 – – – – – – 0.0424
Risk of thyroid cancer 4105 2 1.02 0.25–4.07 – – – – – – 0.9809
Non-Hodgkin lymphoma
Risk of male breast cancer 265 7 2.46 1.16–5.21 – – – – – – 0.0399
Risk of non-Hodgkin
lymphoma
5641 3 1.01 0.323.12 – – – – – – 0.9901
All cancersa
Risk of male breast cancer 148 107 1.58 1.23–2.02 16 2.07 1.23–3.47 1 1.26 0.18–8.98 0.0001
Risk of all cancers 222,859 166 1.35 1.16–1.57 – – – – – – 0.0002
All cancersb
Risk of male breast cancer 185 79 1.32 1.01–1.72 8 1.73 0.85–3.51 – – – 0.0186
Risk of all cancers 146,881 84 1.05 0.85–1.30 – – – – – – 0.6488
Bold and bold italic values indicate that the 99% CI, and 99.9% CI did not overlap with 1.00 respectively
a all cancers include breast cancer and all other cancers
b all cancers include all other cancers except breast cancer
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16.1 for female breast cancer pairs from this Database
(unpublished result).
The association of male breast cancer with ovarian
cancer (p\ 0.0005) could be related to BRCA2 mutations
which have been estimated to account for 20% of Swedish
male breast cancers [7, 12]. Prostate cancer risk is also
increased in BRCA2 mutation carriers but no significant
familial excess was found in the present study although the
trend test was close to being significant (0.0669) for male
breast cancer in prostate cancer families. However, many
male breast cancer patients were diagnosed with second
prostate cancer, and it could be speculated that such double
primary cancers may signal involvement of BRCA2 [7].
The other association with this high level of statistical
support was with female anal cancer. The main risk factor
for anal cancer is infection by human papilloma virus and
genetic predisposition is unknown [15, 16]. Anal cancer is
of squamous cell histology, and curiously squamous cell
skin cancer was a common second cancer diagnosed after
first male breast cancer. Papilloma virus types in skin and
anus are likely to be different and the common denomi-
nator, if any, may be compromised immune function in
some male breast cancer patients [16].
The associations with colorectal, small intestinal and
thyroid cancer, cancer of unknown primary, and non-
Hodgkin lymphoma were based on a single significant
association and need to be confirmed in other settings.
Cancer of unknown primary is a fatal metastatic cancer for
which clinicians and pathologists could not find a primary
site [17]. Familial associations of cancer of unknown pri-
mary with many primary cancers, including female breast
cancer, have been described [18]. None of the cancers
(colorectal, small intestinal and thyroid cancer, cancer of
unknown primary, and non-Hodgkin lymphoma) associated
with male breast cancer are typically manifested in the
BRCA2 syndrome or belong to CHEK2*1100delC associ-
ated cancers which include, in addition to female breast
cancer, stomach, kidney, and prostate cancers and sarcoma
[19]. Small intestinal cancer showed the highest risk for
second cancers after first male breast cancer in the inter-
national consortium study which also reported an increased
risk for rectal cancer [6].
The results for ‘All cancers’ were remarkably high, RR
reaching 2.58 in Table 1 for families of three or more
cancer patients, including female breast cancer. We have
recently characterize familial risks for families presenting
with various cancers, and the present results provide further
evidence for shared familial risks between many cancers
[20–23].
In summary, we provide here novel data for the rare
field of male breast cancer which showed that 16.2% of
male breast cancer patient had a family member with
female breast cancer. All discordant associations were with
cancers which are not typically associated with genes
predisposing to male breast cancer, with the exception of
ovarian cancer, suggesting contribution by BRCA2. The
results support the notion that much of male breast cancer
predisposition is yet unknown [12]. In the same token, the
risks in families with multiple patients with diverse cancers
suggest that high or moderate penetrant genes or environ-
mental factors such as inflammation or smoking could be
involved causing predisposition to many cancers. As fam-
ilies with two male breast cancers could not be found in the
population of 15.7 million individuals, a pedigree-based
gene identification approach for male breast cancer could
include families with single male breast cancers with other
male breast cancer associated cancers.
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